Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Barth Dominik Andreas |

Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen

Barth, D; Stradner, M; Hutterer, H; Spiegelberg, J; Bauernhofer, T; Absenger, G; Jost, P; Pichler, M Blood-based B-cell subtypes as predictors of treatment response during treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2022. 2022; -OeGHO Frühjahrstagung 2022; APR 8-10, 2022; Graz, AUSTRIA. [Poster]

 

Riedl, JM; Barth, D; Steinlechner, S; Moik, F; Posch, F; Schlintl, V; Mayer, MC; Sandner, AM; Berton, F; Koch, L; John, N; Wurm, R; Pichler, M; Absenger, G; Jost, PJ; Wohlkonig, C; Richtig, E; Winder, T; Gerger, A; Terbuch, A Early CRP Kinetics after Initiation of Immune Checkpoint Inhibitors is a predictive Biomarker for Treatment Response independent of the Tumor Antity
ONCOL RES TREAT. 2022; 45(SUPPL 2):228-228.-Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie; Okt 7-10, 2022; Wien. [Poster]
Web of Science

 

Smolle, MA; Helmberg, W; Barth, DA; Sareban, N; Szkandera, J; Liegl-Atzwanger, B; Leithner, A; Pichler, M Prognostic Effect Of Allogeneic Red Blood Cell Transfusions In Soft Tissue Sarcoma Patients. A Retrospective Study.
Advanced Scientific Programme EFORT Congress. 2022; -EFORT Annual Congress; JUN 22-24, 2022; Lisbon, PORTUGAL. [Oral Communication]

 

Smolle, MA; Helmberg, W; Barth, DA; Sareban, N; Szkandera, J; Liegl-Atzwanger, B; Leithner, A; Pichler, M Einfluss der perioperativen Erythrozytenkonzentrat-Gabe auf die Prognose von Weichteilsarkom-patient*Innen. Eine retrospektive Studie.
Abstractband DKOU 2022. 2022; -Deutscher Kongress für Orthopädie und Unfallchirurgie (DKOU); OCT 25-28, 2022; Berlin, GERMANY. [Oral Communication]

 

Seles, M; Smolle, MA; Molnar, A; Riedl, JM;, Barth, DA; Terbuch, A, Rossmann, C; Mannweiler, S; Hutterer, GC, Zigeuner, R; Pummer, K; Smolle-Jüttner, FM; Lindenmann, J; Stotz, MA; gerger, A, Pichler, M; Posch, F. Metastasektomie bei metachron metastasierten Nierenzellkarzinompatient*innen - Wer, wann & wie?
73. Kongress der Deutschen Gesellschaft für Urologie e.V.; SEp 15-18, 2021; Stuttgart, Germany. 2021. [Oral Communication]

 

Barth, DA; Brenner, C; Riedl, JM;Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; Stöger, H; Stotz, M;Gerger, A; Pichler, M External validation of the prognostic relevance of the Advanced Lung Cancer Infammation Index (ALI) in pancreatic cancer patients
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology 2020. 2020; 13 (Suppl 2): 23-65.-Annual Meeting of the Austrian Society of Haematology and Medical Oncology; MAR 19-21, 2020; Vienna, AUSTRIA. [Poster]

 

Posch, F; Barth, D; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Riedl, JM C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: A bi-center study.
ANN ONCOL. 2020; 31: S286-S286.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.234 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Riedl, J; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Schaberl-Moser, R; Stotz, M; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A FOLFIRINOX versus Gemcitabine/nab-Paclitaxel as palliative first-line treatment of advanced pancreatic cancer: An Austrian observational Tri-Center comparative effectiveness analysis.
ONCOL RES TREAT. 2020; 43(SUPPL 4):215-215. [Poster]
Web of Science

 

Riedl, JM; Posch, F; Gantschnigg, A; Horvath, L; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis.
WIEN KLIN WOCHENSCHR. Abstracts 51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin. 2020; 132(SUPPL 2):78-79.-51. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin; SEP 24-26, 2020; Salzburg, AUSTRIA. [Poster]
Web of Science

 

Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Stoger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
ANN ONCOL. 2020; 31: S942-S942.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.2013 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Schwarzenbacher, E; Moik, F; Horvath, L; Renneberg, F; Posch, F; Barth, D; Gantschnigg, A; Schaberl-Moser, R; Pichler, M; Stotz, M; Stoger, H; Ay, C; Greil, R; Gerger, A; Djanani, A; Schlick, K; Riedl, J Incidence, prediction and outcome of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of Gemcitabine/nab-Paclitxel or FOLFIRINOX.
ONCOL RES TREAT. 2020; 43(SUPPL 4):214-214. [Poster]
Web of Science

 

Schwarzenbacher, E; Moik, F; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Barth, D; Stotz, M; Schaberl-Moser, R; Pichler, M; Ay, C; Stoger, H; Greil, R; Djanani, A; Gerger, A; Schlick, K; Riedl, JM Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX.
ANN ONCOL. 2020; 31: S949-S950.-ESMO Virtual Congress; SEP 19-OCT 18, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.08.2035 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

Seles, M; Hutterer, GC; Foßelteder, J; Svoboda, M; Resel, M; Barth, DA; Pichler, R; Bauernhofer, T; Zigeuner, RE; Pummer, K; Slaby, O; Klec, C; Pichler, M Aufschlüsselung der onkogenen Funktionen der langen nicht-kodierende RNA "PANTR1" beim klarzelligen Nierenzellkarzinom.
72. Kongress der Deutschen Gesellschaft für Urologie; Sep, 14-26 2020; Hamburg, Germany/Virtuell. 2020. [Onlinepräsentation]

 

Barth, D; Riedl, JM; Posch, F; Smolle, MA; Kasparek, AK; Niedrist, T; Szkandera, J; Stöger, H; Pichler, M; Gerger, A; Stotz, M Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study.
Proceedings of the Annual Meeting of the Austrian Society of Haematology and Medical Oncology. 2019; -OeGHO Frühjahrstagung 2019; APR 11-13; Linz, AUSTRIA. [Poster]

 

Barth, DA; Riedl, JM; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A External validation and longitudinal extension of the LIPI (lung immune prognostic index) for immunotherapy outcomes in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 108-108. [Poster]
Web of Science

 

Riedl, JM; Barth, D; Posch, F; Foris, V; Absenger, G; Mollnar, S; Pichler, M; Stotz, M; Stoger, H; Olschewski, H; Gerger, A Longitudinal C-reactive protein (CRP) trajectories predict immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer
ONCOL RES TREAT. 2019; 42: 115-115. [Poster]
Web of Science

 

Riedl, JM; Barth, DA; Foris, V; Posch, F; Mollnar, S; Stotz, M; Pichler, M; Stoger, H; Absenger, G; Olschewski, H; Gerger, A External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer
ANN ONCOL. 2019; 30: -44th Congress of the European-Society-for-Medical-Oncology (ESMO); SEP 27-OCT 01, 2019; Barcelona, SPAIN. [Poster]
Web of Science

 

Scheipner, L; Smolle, MA; Barth, D; Posch, F; Stotz, M; Pichler, M; Stöger, H; Gerger, A; Riedl, JM The AST/ALT ratio (de ritis) is an independent prognostic marker for disease free survival in stage II and III colorectal cancer
OeGHO- & AHOP-Frühjahrstagung 2019; 11.04.2019 - 13.04.2019; Linz, AUSTRIA. 2019. [Oral Communication]

 

© Med Uni Graz Impressum